Most recent update: Monday, June 24, 2019 - 17:04

Bariatric News - Cookies & privacy policy

You are here

type 2 diabetes mellitus

Bariatric surgery reduces spending on T2DM and hypertension meds

Patients with severe obesity who undergo bariatric surgery cut their spending on diabetes medications by nearly 65 percent and spending on high blood pressure medications by more than a third three to six months after the operation, according to new research from Rush Medical College in Chicago presented at an American Society for Metabolic and Bariatric Surgery (ASMBS) national clinical symposium on obesity prevention, treatment and research.

Invokana reduces MACE and kidney failure in T2DM patients

The results of a new subgroup analysis from the landmark Phase III CREDENCE study shows Invokana (canagliflozin) significantly reduced the risk of major cardiovascular (CV) events and kidney failure in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in patients with and without known cardiovascular (CV) disease. The results were presented at the American Diabetes Association’s 79th Scientific Sessions in San Francisco.

Fractyl’s Revita DMR procedure has potential to end insulin injections

Fractyl Laboratories has presented interim data from the investigator-initiated INSPIRE clinical trial in collaboration with Fractyl showing Revita DMR, a same-day therapeutic procedure, can help eliminate the need for daily insulin injections for type 2 diabetes (T2D) patients. This data was revealed at the American Diabetes Association's 79th Scientific Sessions in San Francisco, during a presentation (1156-P) is entitled, ‘Duodenal Mucosal Resurfacing (DMR) Combined with GLP-1-RA May Eliminate Insulin Therapy and Improve Metabolic Health in Type 2 Diabetes.’

Higher BMI linked with increased risk of serious health problems

A new study has shed light on the link between higher body mass index (BMI) and serious health outcomes and death in over 2.8 million adults representative of the UK population. The new estimates, presented at this year's European Congress on Obesity (ECO) in Glasgow, UK, indicate that adults with severe obesity class III (BMI40-45) are 12 times as likely to develop type 2 diabetes and are at 22 times greater risk of sleep apnoea than their normal weight peers. Those individuals with obesity class I (BMI30-35) are at 70% higher risk of developing heart failure.

How epigenetics impacts obesity and type 2 diabetes

In the past decade, knowledge of how lifestyle affects our genes (epigenetics) has grown exponentially. Researchers at Lund University have summarised the state of scientific knowledge within epigenetics linked to obesity and type 2 diabetes in a review article published in the scientific journal Cell Metabolism.

Oestrogen can decrease insulin resistance reducing T2DM

The results of a Texas A&M University-led study provide insights into the mechanism by which oestrogen can decrease insulin resistance and the production of glucose, reducing incidences of Type 2 diabetes mellitus. Recent research on the prevalence of Type 2 diabetes has shown gender-related differences, especially a reduced incidence of the disease in premenopausal women. Clinical and animal studies have shown a strong correlation between oestrogen deficiency and metabolic dysfunction.

Novo Nordisk launches semaglutide once-weekly GLP-1 RA for T2DM

Novo Nordisk UK has announced that Ozempic (semaglutide), a once-weekly GLP-1 analogue injection1 for the treatment of type 2 diabetes is now available in the UK. According to the company, Ozempic works by mimicking the function of the GLP-1 (human glucagon-like peptide-1) hormone produced in the gut that lowers post-meal blood glucose levels and also slows glucose absorption into the bloodstream.

VAT prioritisation may cause pathogenic obesity

Type-2 (adult-onset) diabetes and other diseases related to the obesity epidemic depend on how the body stores excess energy, according to evolutionary biologist, Dr Mary Jane West-Eberhard, emeritus scientist at the Smithsonian Tropical Research Institute. West-Eberhard describes her theory about fat inside the abdominal cavity (visceral adipose tissue or VAT), the ‘VAT prioritisation hypothesis.’

Obesity associated with an increased risk of T2DM and CAD

Obesity is associated with an increased risk of T2DM and coronary artery disease (CAD) and should remain a major focus of public health initiatives, according to a genetic analysis by the Cleveland Clinic. Interestingly, the researchers found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of T2DM and CAD.

Surgery reduces macrovascular events in T2DM patients

People with T2DM and severe obesity who had bariatric surgery were 40 percent less likely to have a heart attack or stroke within five years than those who had usual medical care for their diabetes, according to a study at four systems in the Health Care Systems Research Network. During the same period, those who had surgery were also more than one-third less likely to develop heart disease and two-thirds less likely to die from any cause.

Subscribe to RSS - type 2 diabetes mellitus